| Jonathan E Kass, MD | |
|
3 Cooper Plz, Suite 215, Camden, NJ 08103-1438 | |
| (856) 342-2439 | |
| (856) 342-7832 |
| Full Name | Jonathan E Kass |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 45 Years |
| Location | 3 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700974441 | NPI | - | NPPES |
| 0527568000 | Other | AMERIHEALTH, KEYSTONE, IBC | |
| 123454 | Other | AETNA | |
| 110084287 | Other | NJ | RR MEDICARE |
| 1010222 | Other | HORIZON NJ HEALTH | |
| 5170800 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MA56734 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cooper University Hospital | Camden, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cmc Department Of Medicine Group Pa | 2163335878 | 329 |
News Archive
Counseling about alcohol misuse can reduce the number of drinks consumed weekly among adults with risky drinking habits, according to a review of the evidence.
Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
› Verified 6 days ago
| Entity Name | Cmc Department Of Medicine Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679605554 PECOS PAC ID: 2163335878 Enrollment ID: O20050203000280 |
News Archive
Counseling about alcohol misuse can reduce the number of drinks consumed weekly among adults with risky drinking habits, according to a review of the evidence.
Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
› Verified 6 days ago
| Entity Name | Cmc Department Of Medicine Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265565667 PECOS PAC ID: 2163335878 Enrollment ID: O20050504000294 |
News Archive
Counseling about alcohol misuse can reduce the number of drinks consumed weekly among adults with risky drinking habits, according to a review of the evidence.
Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan E Kass, MD 3 Cooper Plz, Suite 215, Camden, NJ 08103-1438 Ph: (856) 342-2439 | Jonathan E Kass, MD 3 Cooper Plz, Suite 215, Camden, NJ 08103-1438 Ph: (856) 342-2439 |
News Archive
Counseling about alcohol misuse can reduce the number of drinks consumed weekly among adults with risky drinking habits, according to a review of the evidence.
Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.
Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
› Verified 6 days ago
Howard Isadore Kesselheim, D.O. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2 Cooper Plz, Camden, NJ 08103 Phone: 855-632-2667 | |
Richard Arthur Hellander, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 817 Federal St, Camden, NJ 08103 Phone: 856-583-2400 | |
Sivakoti Nagireddy Guda, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Haddon Ave Fl 6, Camden, NJ 08103 Phone: 856-757-3500 | |
Steven Mudroch Ii, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3 Cooper Plz Rm 513, Camden, NJ 08103 Phone: 856-963-3715 Fax: 856-635-1052 | |
Dr. Bradley Foster Bender, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-3150 | |
Dr. Amanda A Valvano, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Niku Thomas, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2488 |